Acute Leukemia. Sebastian Giebel. Geneva 03/04/
|
|
- Alexis Garrison
- 5 years ago
- Views:
Transcription
1 Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012
2 Acute leukemias: EBMT survey 2
3 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant
4 Acute leukemias: INCIDENCE Dores GM, Blood
5 Acute leukemias: PATHOGENESIS 5
6 Acute leukemias: DIAGNOSIS AML ALL Atlas of Hematology, Nagoya University School of Medicine Department of Medicine The Branch Hospital, Takuji Ichihashi, December 1996 Bone marrow cytology: >20% blasts Peripheral blood: anemia, neutropenia, thromboctopenia Organ lesions: spleen, lymph nodes, liver, mediastinum, CNS 6
7 Acute leukemias: DIAGNOSIS Diagnostic methods to establish type and subtype of acute leukemia, and risk subgroup: Cytology of bood/bone marrow Immunophenotyping (detection of specific markers of leukemic cells with the use of flow cytometry) Cytogenetics (detection of chromosomal abnormalities) Molecular genetics (detection of gene mutations, sometimes corresponding with chromosomal abnormalities) Acute Lukemia (including ALL) 7
8 Acute leukemias: DIAGNOSIS Acute Lukemia (including ALL) 8
9 Acute leukemias: DIAGNOSIS Immunophenotyping: Subtypes of ALL 9
10 Acute leukemias: DIAGNOSIS Cytogenetics: detection of chromosomal abnormalities Spanish National Cancer Research Center Acute Lukemia (including ALL) 10
11 Acute leukemias: DIAGNOSIS Genetic diversity of AML Dohner H, et al. Blood 2010 Acute Lukemia (including ALL) 11
12 Acute leukemias: DIAGNOSIS Genetic diversity of ALL Faderi S, et al., Cancer 2003 Acute Lukemia (including ALL) 12
13 Acute leukemias: DIAGNOSIS Cytogenetics: classification of AML and ALL t(8;21)(q22;q22) = AML1/ETO Sakai C, Internal Medicine
14 Acute leukemias: DIAGNOSIS Cytogenetics: classification of AML 14
15 Acute leukemias: DIAGNOSIS Cytogenetics: classification of ALL 15
16 Acute leukemias: DIAGNOSIS 16
17 Acute leukemias: PROGNOSTIC FACTORS Cytogenetic and molecular markers Complex karyotype De Souza Fernandez T, Brazilian J Genetics
18 AML: PROGNOSTIC FACTORS Risk group Subsets Favorable t(8;21)(q22;q22); RUNX1-RUNX1T1(AML1-ETO) inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3-ITD (normal karyotype) Mutated CEBPA (normal karyotype) Intermediate-I Mutated NPM1 and FLT3-ITD (normal karyotype) Wild-type NPM1 and FLT3-ITD (normal karyotype) Wild-type NPM1 and FLT3 (normal karyotype) Intermediate-II t(9;11)(p22;q23); MLLT3-MLL Cytogenetic abnormalities not classified as favorable or adverse Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 t(6;9)(p23;q34); DEK-NUP214(CAN) t(v;11)(v;q23); MLL rearranged -5 or del(5q); -7; 17p abnormalities; complex karyotype Dohner H, et al. Blood
19 AML: PROGNOSTIC FACTORS AML: Survival according to genetically defined risk groups Rollig C, J Clin Oncol
20 AML: PROGNOSTIC FACTORS AML: Survival after allohsct according to genetically defined risk groups Armand P, Biol Blood Marrow Transplant
21 ALL: PROGNOSTIC FACTORS ALL: Survival according to the presence of Ph chromosome i.e. t(9;22) or BCR/ABL Goldstone AH, Blood
22 Acute leukemias: PROGNOSTIC FACTORS 22
23 Acute leukemias: PROGNOSTIC FACTORS 23
24 Acute leukemias: PROGNOSTIC FACTORS 24
25 Acute leukemias: TREATMENT AML/ALL INDUCTION CR CONSOLIDATION High risk DONOR+ Standard risk DONOR- ALLO-HSCT AUTO-HSCT Maintenance CHT Observation 25
26 AML: INDICATIONS FOR ALLO-HSCT 1 st COMPLETE REMISSION Sibling MUD GIMEMA HR, IR HR, IR-MRD(+) NILG UK HR, IR Fl3-ITD.(+), MLL(+), WBC >50, long time to CR, M0M6M7, hepatosplenomegaly, Sec/MDS Poor risk calculated based on: age, sex, status post Ind1, cytogenetics, WBC, SecAML PETHEMA HR, IR HR PALG HR, IR HR, IR Primary induction failure Relapse, after salvage cht. ALWP EBMT Educational Symposium, Milan 2010, By courtesy of Fabio Ciceri 26
27 Acute leukemias: TREATMENT DGN PRETREATMENT: PDN PALG ALL6 Ph(-) INDUCTION I: DNR/VCR/PEGAsp/PDN CR, MRD-I <0.1% CR, MRD-I 0.1%; NR <40 y 40y, CD52(-) >40 y, CD52(+) MRD-I INDUCTION II: FLAM INDUCTION II: MiniFLAM INDUCTION II: FLAM-CAMP MRD-II 40 y <40 y CR NR CONSOLIDATION I: ID-Mtx/Vep/Dexa CONSOLIDATION I: HD-Mtx/Vep/Dexa Experimental therapy MRD-III CONSOLIDATION II: Cy/HD-AraC/PEGAsp MRD-IV MRD-I 0.1% and/or MRD-III,IV 0.05% MRD-I <0.1% and MRD-III,IV <0.05% Donor(+) Donor(-) CONSOLIDATION III: ID- or HD-Mtx/Vep/Dexa MRD-V Sib/MUD-alloHSCT CONSOLIDATION III: FLAM lub HyperCVAD AutoHSCT MAINTENANCE: 8xMP/Mtx/DNR/VCR/PDN 8xMP/Mtx/DNR/PDN AutoHSCT MAINTENANCE: 12xMP/Mtx 27
28 Acute leukemias: DIAGNOSIS Response to therapy: Complete remission normal blood count, <5% blasts in bone marrow, no organ lesions Cytogenetic remission disappearance of chromosomal abnormalities present at diagnosis Molecular remission - disappearance of gene mutations present at diagnosis Acute Lukemia (including ALL) 28
29 Acute leukemias: TREATMENT 29
30 Acute leukemias: DISEASE HISTORY 30
31 Acute leukemias: DISEASE STATUS AT AUTOLOGOUS CELL COLLECTION 31
32 Acute leukemias: DISEASE STATUS AT STEM CELL COLLECTION/TRANSPLANTATION 32
Trapianto allogenico convenzionale
Il trapianto nella leucemia acuta mieloide a rischio intermedio Trapianto allogenico convenzionale Trapianto allogenico nelle Leucemie Acute Mieloidi in I RC D. Pastore Ematologia con Trapianto-Bari Domenico
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationExamining Genetics and Genomics of Acute Myeloid Leukemia in 2017
Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017 Elli Papaemmanuil, PhD Memorial Sloan Kettering Cancer Center New York, New York, United States Today s Talk Cancer genome introduction
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationWHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationUpdate on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationAcute myeloid leukemia: a comprehensive review and 2016 update
OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationPh+ALL : a new era. Said Y Mohamed KFSHRC, Riyadh Ain Shams University, Cairo, Egypt
Ph+ALL : a new era Said Y Mohamed KFSHRC, Riyadh Ain Shams University, Cairo, Egypt A 30 Y/O patient with Ph+ ALL What would you start as an induction? 1. BFM/CALGB/UKALL Plus TKI? 2. Some chemo + TKI.
More informationACUTE LEUKEMIA. Zwi N. Berneman University of Antwerp & Antwerp University Hospital. 16th Post-ASH Meeting Zaventem, 10 January 2014
ACUTE LEUKEMIA Zwi N. Berneman University of Antwerp & Antwerp University Hospital 16th Post-ASH Meeting Zaventem, 10 January 2014 ACUTE MYELOID LEUKEMIA HIGH-RISK AML Clinically and biologically distinct
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Effective Date: June, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team and are a synthesis of currently accepted
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationHematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Policy Number: Original Effective Date: MM.07.008 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 02/23/2018 Section:
More informationKeywords: Acute Myeloid Leukemia, FLT3-ITD Mutation, FAB Subgroups, Cytogenetic Risk Groups
Original Articleeee fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007-2008 Emami AH, 1 Shekarriz
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationFluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)
PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationMyeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant
Original Article http://dx.doi.org/1349/ymj.212.53.3.53 pissn: 513-5796, eissn: 1976-2437 Yonsei Med J 53(3):53-536, 212 Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 24 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Aliyah Rahemtullah 1, Martin K Selig 1, Paola Dal Cin 2 and Robert P Hasserjian 1 Departments of Pathology,
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationFLT-3 inhibitors in AML
FLT-3 inhibitors in AML Jorge Sierra Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona Rome, September 24, 2017 Disclosures Advisory board: Pfizer, NovarHs, Jazz, Celgene, SeaIle
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationTHE LEUKEMIAS. ACUTE CHRONIC AML and ALL CLL and CML (any ages) (in the elderly)
THE LEUKEMIAS Definition: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues THE LEUKEMIAS Characteristics: maturation
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationGENETICS OF HEMATOLOGICAL MALIGNANCIES
de DUVE INSTITUTE GENETICS OF HEMATOLOGICAL MALIGNANCIES INTERUNIVERSITY CERTIFICATE IN HUMAN GENETICS Université catholique de Louvain Brussels,19/02/2016 Professor Hélène Antoine-Poirel, MD, PhD Center
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,
More informationKylie Lepic BSc, MD, FRCPC CAGPO Conference
Acute Leukemia Kylie Lepic BSc, MD, FRCPC CAGPO Conference Oct 19, 2013 1 Disclosures No conflicts of interest 2 Objectives Case presentation Classification of leukemia Clinical manifestations Diagnosis
More informationInitial Diagnostic Workup of Acute Leukemia
Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine
More informationHSCT - Minimum Essential Data - A REGISTRATION - DAY 0
HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?:
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationTest Name Results Units Bio. Ref. Interval. Positive
Lab No 135091548 Age 35 Years Gender Female 1/9/2017 120000AM 1/9/2017 103420AM 4/9/2017 23753M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE 3 t (1;19)
More informationReview Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Review Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? Federico Mosna 1, *, Debora Capelli 2 and Michele Gottardi 3 1 Hematology and Bone Marrow Transplantation Unit, Ospedale
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationallosct and CLL in the BCRi era time for a study
allosct and CLL in the BCRi era time for a study Patient characteristics in BCRi studies and allosct candidates DIFFER Facts on BCRi no Cure Risk factors for shorter BCRi efficacy in MV analysis? PA-refractory
More informationDr. Anjali Kelkar (DNB Path, IFCAP)
Acute Leukemias : Morphology and Beyond Dr. Anjali Kelkar (DNB Path, IFCAP) Consultant - Diagnostic Haematology NABL Assessor Senior Associate Professor, Incharge Haematology Labs Bharati Vidyapeeth Deemed
More information«Adverse Prognosis» Acute Myeloid Leukemia
23. Fortbildungskurs Lausanne, 11.11.2017 «Adverse Prognosis» Acute Myeloid Leukemia Markus G. Manz Zentrum für Hämatologie und Onkologie UniversitätsSpital Zürich Content AML Update on current definition
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationMeasurable/Minimal Residual Disease in Patients with Acute Myeloid Leukemia Undergoing Transplantation
Measurable/Minimal Residual Disease in Patients with Acute Myeloid Leukemia Undergoing Transplantation June 9, 2018 Dave Sanford The Leukemia/Bone Marrow Transplant Program of British Columbia Disclosures
More informationWednesday, November 30, 2011 University of Michigan
Wednesday, November 30, 2011 University of Michigan Presenter Gary J. Schiller, MD, FACP Professor, Department of Medicine, Hematology/Oncology Director, Hematological Malignancies/Stem Cell Transplantation
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationPage: 1 of 12. Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia
Page: 1 of 12 Last Review Status/Date: September 2015 Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Description Treatment of acute myeloid leukemia (AML) is based upon risk stratification,
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationAML with t(8;16) shows unique clinical, morphological and cytogenetic features
AML with t(8;16) shows unique clinical, morphological and cytogenetic features G A B R I E L A G H E O R G H E, M D C H I L D R E N S H O S P I T A L W I S C O N S I N, M E D I C A L C O L L E G E O F
More informationOncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
The Oncologist Pediatric Oncology Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia SOHEIL MESHINCHI, a ROBERT J. ARCECI b a Fred Hutchinson Cancer Research Center, University
More informationWHO Classification 7/2/2009
Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationCase 089: Therapy Related t(8;21)(q22;q22) AML and
Case 089: Therapy Related t(8;21)(q22;q22) AML and SM-AHNMD ST Pullarkat 1, V Pullarkat 2, SH Kroft 3, CS Wilson 4, M Thein 5, WW Grody 1, and RK Brynes 5 1 UCLA, 2 City of Hope National Med Ctr, 3 Med
More informationDisclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.
RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More information